These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34997957)

  • 61. Concurrent Cobalamin C and Plasminogen Deficiencies in a Patient with Chronic Thrombotic Microangiopathy.
    Dirim AB; Safak S; Balci MC; Ozyavuz P; Garayeva N; Tiryaki TO; Oto OA; Ozluk Y; Kilicaslan I; Solakoglu S; Artan AS; Yazici H; Turkmen A; Ozturk S
    Nephron; 2024; 148(1):54-62. PubMed ID: 37611544
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Atypical hemolytic uremic syndrome (aHUS): new insights into pathogenesis leading to novel therapeutic approaches].
    Kistler AD
    Praxis (Bern 1994); 2016 Mar; 105(7):389-96. PubMed ID: 27005733
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Hemolytic uremic syndrome in the setting of COVID-19 successfully treated with complement inhibition therapy: An instructive case report of a previously healthy toddler and review of literature.
    Matošević M; Kos I; Davidović M; Ban M; Matković H; Jakopčić I; Vuković Brinar I; Szilágyi Á; Csuka D; Sinkovits G; Prohászka Z; Vrljičak K; Lamot L
    Front Pediatr; 2023; 11():1092860. PubMed ID: 36873657
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Ocular thrombotic microangiopathy in atypical hemolytic-uremic syndrome (a clinical case study)].
    Smirnova TV; Sheludchenko VM; Kozlovskaya NL; Kazaryan EE; Andzhelova DV; Sherstneva LV; Velieva IA; Kuchieva AM; Akaeva MI
    Vestn Oftalmol; 2018; 134(5. Vyp. 2):215-226. PubMed ID: 30499520
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy.
    Moscvin M; Liacos CI; Chen T; Theodorakakou F; Fotiou D; Hossain S; Rowell S; Leblebjian H; Regan E; Czarnecki P; Bagnoli F; Bolli N; Richardson P; Rennke HG; Dimopoulos MA; Kastritis E; Bianchi G
    Blood Cancer J; 2023 Feb; 13(1):31. PubMed ID: 36849497
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy.
    Haydock L; Garneau AP; Tremblay L; Yen HY; Gao H; Harrisson R; Isenring P
    J Mol Med (Berl); 2022 Feb; 100(2):269-284. PubMed ID: 34714369
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Relapse of atypical hemolytic uremic syndrome triggered by COVID-19: a lesson for the clinical nephrologist.
    Uwatoko R; Shindo M; Hashimoto N; Iio R; Ueda Y; Tatematsu Y; Kato N; Maruyama S; Hayashi T
    J Nephrol; 2023 Jun; 36(5):1439-1442. PubMed ID: 36877369
    [No Abstract]   [Full Text] [Related]  

  • 68. Adrenocortical carcinoma complicated by renal thrombotic microangiopathy, a case-series.
    de Nattes T; Moreau-Grangé L; Vezzosi D; Hadoux J; Hie M; Guerrot D; Grangé S
    BMC Nephrol; 2020 Jan; 21(1):35. PubMed ID: 32000700
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Hemolytic uremic syndrome with multiple organ involvement secondary to complement factor H p.Arg1215X mutation.
    Yeşilbaş O; Şevketoğlu E; Petmezci MT; Kıhtır HS; Benzer M; Berdeli A
    Turk J Pediatr; 2017; 59(5):576-580. PubMed ID: 29745120
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Complement factor H gene polymorphisms and vivax malaria associated thrombotic microangiopathy.
    Agrawal P; Kumar A; Parwaiz A; Rawat A; Tiewsoh K; Nada R
    Saudi J Kidney Dis Transpl; 2019; 30(2):540-544. PubMed ID: 31031394
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Shiga Toxin as a Potential Trigger of CFHR1 Deletion-Associated Thrombotic Microangiopathy.
    Nalluru SS; Sridharan M; Go RS; Said S; Marshall AL
    Am J Med Sci; 2018 Nov; 356(5):492-498. PubMed ID: 30177262
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Atypical Hemolytic Uremic Syndrome Associated with Complement Factor H Mutation and IgA Nephropathy: A Case Report Successfully Treated with Eculizumab.
    Nakamura H; Anayama M; Makino M; Makino Y; Tamura K; Nagasawa M
    Nephron; 2018; 138(4):324-327. PubMed ID: 29241200
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Lessons for the clinical nephrologist: recurrent pregnancy-associated thrombotic microangiopathy (TMA) with a known complement mutation and features of preeclampsia; a diagnostic and therapeutic dilemma.
    Smith P; Abdelmaguid A; Clark K; Bramham K
    J Nephrol; 2021 Oct; 34(5):1673-1676. PubMed ID: 34097294
    [No Abstract]   [Full Text] [Related]  

  • 74. Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti-Factor H IgAλ Antibody.
    Rigothier C; Delmas Y; Roumenina LT; Contin-Bordes C; Lepreux S; Bridoux F; Goujon JM; Bachelet T; Touchard G; Frémeaux-Bacchi V; Combe C
    Am J Kidney Dis; 2015 Aug; 66(2):331-6. PubMed ID: 26015278
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [The revolution of monoclonal antibodies in the treatment of thrombotic microangiopathy].
    Sauvètre G; Grange S; Froissart A; Veyradier A; Coppo P; Benhamou Y
    Rev Med Interne; 2015 May; 36(5):328-38. PubMed ID: 25547956
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Renal Damage in Recurrent Atypical Hemolytic Uremic Syndrome Associated with C3 p.Ile1157Thr Gene Mutation.
    Okabe M; Kobayashi A; Marumoto H; Koike K; Yamamoto I; Kawamura T; Tsuboi N; Yokoo T
    Intern Med; 2021 Mar; 60(6):917-922. PubMed ID: 33087669
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.
    Krishnappa V; Gupta M; Elrifai M; Moftakhar B; Ensley MJ; Vachharajani TJ; Sethi SK; Raina R
    Ther Apher Dial; 2018 Apr; 22(2):178-188. PubMed ID: 29250893
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Syndromes of thrombotic microangiopathy associated with pregnancy.
    George JN; Nester CM; McIntosh JJ
    Hematology Am Soc Hematol Educ Program; 2015; 2015():644-8. PubMed ID: 26637783
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors.
    Le Clech A; Simon-Tillaux N; Provôt F; Delmas Y; Vieira-Martins P; Limou S; Halimi JM; Le Quintrec M; Lebourg L; Grangé S; Karras A; Ribes D; Jourde-Chiche N; Rondeau E; Frémeaux-Bacchi V; Fakhouri F
    Kidney Int; 2019 Jun; 95(6):1443-1452. PubMed ID: 30982675
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Eculizumab Modifies Outcomes in Adults with Atypical Hemolytic Uremic Syndrome with Acute Kidney Injury.
    Cao M; Leite BN; Ferreiro T; Calvo M; Fernández C; Alonso Á; Rodriguez A; Salvador P; Seijo R; Pita S; Arjona E; Rodríguez de Córdoba S; Valdés Cañedo F
    Am J Nephrol; 2018; 48(3):225-233. PubMed ID: 30205388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.